Novo Nordisk A/s

Ulla Ribel-Madsen

Peter Madsen

Henrik Bengtsson

Palle Jakobsen

Svend Havelund

Thomas Hoeg-Jensen

Ib Jonassen

Frantisek Hubalek

Svend Ludvigsen

Helle Birk Olsen

Tina Møller Tagmose

Jeppe Sturis

Per Balschmidt

Lars Eilertsen

Morten Schlein

Ulrich Sensfuss

Peter Kresten Nielsen

Jonas Kildegaard Pedersen

Christian Fledelius

Helle Naver

Inger Lautrup-Larsen

Per Nørgaard

Rikke Bjerring Andersen

Anne Plum

Kezia A Juul

The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.

Insulin compositions and method of making a composition

A drug delivery assembly includes a housing (), a piston () axially displaceable in the housing, and a variable volume reservoir () formed by the housing and the piston and containing a fluid first drug. The assembly further includes an exterior fluid inlet () arranged in or configured to be arranged in fluid communication with the reservoir, a fluid outlet () arranged in or configured to be arranged in fluid communication with the reservoir, biasing means () configured for moving the piston forwards, and releasable retaining means () configured for retaining the piston in an initial position, whereby the biasing means is allowed to move the piston forwards to expel fluid drug from the reservoir when the retaining means is released.

Drug filled delivery assembly

The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of treating diabetes mellitus using these insulin analogues is also provided.

Protease resistant insulin analogues

The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the &#x3b1;-amino group of the N-terminal amino acid residue of the B chain or to the &#x3b5;-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula:&#x2014;W&#x2014;X&#x2014;Y&#x2014;Zwherein W, X, Y and Z are as defined in the disclosure.

Insulin derivatives

Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.

Preparation comprising insulin, nicotinamide and an amino acid

The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the &#x3b1;-amino group of the N-terminal amino acid residue of the B chain or to the &#x3b5;-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula:-W-X&#x2014;Y-Zwherein W, X, Y and Z are as defined in the disclosure.

Growing community of inventors

Virum, Denmark

Ulla Ribel-Madsen